Modulating COVID-19 disease by targeting virus and virus-induced responses through pharmaceutical and mechanical ventilation strategies: SARS-CoV-2 S-protein, ACE2 and TMPRSS2
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA143552
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$471,642Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
Flinders UniversityResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Disease pathogenesisSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
COVID-19 is a current global pandemic that is likely to be an on-going threat. We need a multipronged strategy to combat COVID-19, including therapeutic anti-virals and clinical practice management strategy. We will address both these points to define the mechanisms triggering disease, test existing drugs targeting androgens and modify the way doctors use ventilators to treat COVID-19 disease in the intensive care unit. Outcomes will have impact beyond COVID-19 for managing viral lung disease.